Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 26, 2015 7:29 PM ET

Pharmaceuticals

Company Overview of Intas Pharmaceuticals Ltd.

Company Overview

Intas Pharmaceuticals Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations. The company offers pharmaceutical products for various therapeutic areas, including neurology, psychiatry, cardiology, pain management, gastroenterology, diabetology, nephrology, urology, anti-infective therapy, dermatology, gynecology, respiratory system, hematology, and ophthalmology, as well as chronic therapy areas relating to neurology, psychiatry, cardiology, and diabetology; and Rituximab, a drug to treat Non-Hodgkin's Lymphoma (a type of blood cancer). The company also engages in in-licensing a lipid-based new drug delivery system platform for developing and commercializi...

Chinubhai Centre

Off Nehru Bridge

Ashram Road

Ahmedabad,  380009

India

Founded in 1985

8,314 Employees

Phone:

91 79 2657 6655

Fax:

91 79 2657 8862

Key Executives for Intas Pharmaceuticals Ltd.

Chief Executive Officer, Managing Director, Director, Member of Share Allotment Cum Transfer Committee, Member of Investor Grievance Committee and Member of IPO Committee
Age: 53
Founder and Chairman
Age: 81
Chief Finance Officer, Member of Share Allotment cum Transfer Committee and Member of IPO Committee
Age: 50
President of Accord Healthcare Inc.
Age: 50
President (U S A) of Accord Healthcare Incorporated
Age: 46
Compensation as of Fiscal Year 2014.

Intas Pharmaceuticals Ltd. Key Developments

Intas Launches Biosimilar Version of Amgen's Neupogen in Europe

Intas has launched a biosimilar version of Amgen's (US) neutropaenia drug Neupogen (filgrastim). The injectable drug is the first biosimilar manufactured by an Indian company to be approved in the tightly regulated EU market. According to a company statement, Phase III clinical trials (multi-centre safety and efficacy studies involving 120 female adult patients receiving chemotherapy to treat breast cancer) showed that Intas's filgrastim reduced severe neutropaenia to 1.4 days from an average of 1.6 and 1.8 days reported in other studies. Intas has confirmed that its lower-cost version of filgrastim, marketed under the brand name Accofil, has secured UK and Dutch tendering contracts, and expects to launch in Mexico and Brazil in the next six months. The company is looking to file for US approval in 2016, but would face competition at launch from Sandoz (subsidiary of Swiss firm Novartis), which has already filed for approval for Zarxio, another biosimilar version Neupogen. It is anticipated that the US FDA is likely to make a final decision regarding the approval of Zarxio in March.

Investors Reportedly Eyes Stake In Intas

Temasek Capital, GIC Pte. Ltd., and Capital International, Inc. are in independent talks to purchase ChrysCapital's 10% stake in Intas Pharmaceuticals Ltd. for about $150 million, three people with direct knowledge of the development said. An investment banker said, "Chrys-Capital is looking to sell part of its 16.5% stake after Intas Pharma postponed its initial public offering due to muted market conditions." "Yes, ChrysCapital is looking for partial exit from the company and the IPO plan was also formulated with the objective of providing exit," Jayesh Shah, Chief Financial Officer of Intas Pharma said in an email response. "However, Intas is still evaluating various options to provide meaningful exit to ChrysCapital and nothing has been concretised so far." Another person familiar with the matter said, "Along with the partial exit of the existing investor, the promoters could look at raising fresh funds for the company." "No valuation number has been frozen," said Shah of Intas.

PE Firms Reportedly Mulls $150 Million Stake Buy In Intas

Temasek, Goldman Sachs and Warburg Pincus have approached Intas Pharmaceuticals Ltd. for a stake purchase after the company deferred its initial public offer plans, said people familiar with the matter. The potential investors are eyeing the shares of private equity fund ChrysCapital, which sought a partial exit through a listing. Chief Financial Officer, Jayesh Shah said Intas had been approached by possible new investors for the past 24 months. "We are not in serious talks and we have not come to any conclusion of any option yet," he said. Intas has also not finalized any valuation right now, he added. ChrysCapital was unavailable for comments, Temasek declined to comment on speculation while an emailed query to Goldman Sachs went unanswered and Warburg Pincus could not be reached immediately, according to sources.

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 2, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Intas Pharmaceuticals Ltd., please visit www.intaspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.